ActoBio Therapeutics™

@ActobioT

ActoBio Therapeutics, Inc. is pioneering a new class of microbe-based ActoBiotics® biopharmaceuticals.

Vrijeme pridruživanja: rujan 2018.

Tweetovi

Blokirali ste korisnika/cu @ActobioT

Jeste li sigurni da želite vidjeti te tweetove? Time nećete deblokirati korisnika/cu @ActobioT

  1. 2. pro 2019.

    Great news from our partners at ! Enrollment is now complete for their phase 2 clinical trial of AG013 for . AG013 is an ActoBio Therapeutics Inc. candidate created on our ® platform and licensed to Oragenics. More:

    Poništi
  2. 22. lis 2019.

    If you’re at don’t miss Therapeutics™ CEO Pieter Rottiers presenting an overview of the innovative ActoBiotics® platform on Wednesday October 23 @ 9:15 AM. Read more: or follow us on LinkedIn or Twitter

    Poništi
  3. 1. lis 2019.

    If you're at , don't miss Therapeutics™ CEO Pieter Rottiers' presentation at 4PM today about the innovative ActoBiotics® platform. More: or follow us on Twitter or LinkedIn.

    Poništi
  4. 13. ruj 2019.

    If you're attending don't miss Therapeutics™ CEO Pieter Rottiers' overview of the innovative ® platform and its applications on October 1. Read more: , follow us on Linkedin or Twitter

    Poništi
  5. 19. kol 2019.

    Therapeutics™ Receives IND Green Light for New Antigen-Specific Immunotherapy Study Aimed at Improving Celiac Patients' Tolerance of Gluten. Read more: or follow us on LinkedIn or Twitter

    Poništi
  6. 17. srp 2019.

    An interesting and thought-provoking article on the future of diabetes treatments from Read more about at

    Poništi
  7. 1. srp 2019.

    Therapeutics™ Progresses AG019 to Next Stage of a Phase Ib/IIa Clinical Study for the Treatment of . Read more: or follow us on LinkedIn or Twitter

    Poništi
  8. 26. lip 2019.

    Reminder: If you're at , don't miss Therapeutics™ CTO Lothar Steidler's presentation on Friday June 28. He will discuss the innovative ActoBiotics® platform and its applications. Read more:

    Poništi
  9. 19. lip 2019.

    Reminder: Therapeutics™ CTO Lothar Steidler has been invited to present at the on Friday June 28 in Boston. He will discuss the innovative ActoBiotics® platform and its applications. Read more:

    Poništi
  10. 12. lip 2019.

    Therapeutics™' CTO Lothar Steidler has been invited to talk about our innovative ActoBiotics® platform and its applications at in Boston, on Friday June 28 at 3:50pm. Read more:

    Poništi
  11. 31. svi 2019.

    Reminder: Don't miss Therapeutics™ CEO Pieter Rottiers' overview of the innovative ® platform at on Monday 3rd June, at 14:15. Read more: or follow us on LinkedIn or Twitter

    Poništi
  12. 29. svi 2019.

    If you are attending , don't miss Pieter Rottiers' overview of the innovative ActoBiotics® platform on Monday 3rd June, at 14:15.

    Poništi
  13. 22. svi 2019.

    ActoBio Therapeutics™ CEO Pieter Rottiers will be presenting at 2019 on Monday 3rd June, at 14:15. Read more: or follow us on LinkedIn or Twitter .

    Poništi
  14. 20. svi 2019.

    Reminder: ActoBio Therapeutics™ CEO Pieter Rottiers is at Europe 2019 from 20 - 21 May 2019 in Barcelona. Read more: , LinkedIn or Twitter .

    Poništi
  15. 15. svi 2019.

    ActoBio Therapeutics™ CEO Pieter Rottiers will be attending Europe 2019 from 20 - 21 May 2019 in Barcelona. Read more: , LinkedIn or Twitter .

    Poništi
  16. 24. tra 2019.

    ActoBio Therapeutics™ are proud to announce that CTO Lothar Steidler has been elected VIB Alumni Awardee 2019. Read more:

    Poništi
  17. proslijedio/la je Tweet
    3. tra 2019.

    With the therapeutic potential of engineered cells, we may be closer than ever to curing diseases like type 1

    Poništi
  18. Reminder: CEO Pieter Rottiers will participate in a panel discussion at 2nd Antigen-Specific Immune Tolerance Drug Development Summit in Boston on 28th March. Read more: or LinkedIn.

    Poništi
  19. ActoBio Therapeutics™ @ Antigen-Specific Immune Tolerance Drug Development Summit 2019: CEO Pieter Rottiers invited to take part in panel discussion in Boston on Thursday 28th March at 16:30. Read more: or LinkedIn.

    Poništi
  20. Reminder: ActoBio Therapeutics™ CTO Lothar Steidler will talk about our innovative ActoBiotics® platform and its applications at Pharmabiotics 2019 in Paris, 13th – 14th March 2019. Read more:

    Poništi

Čini se da učitavanje traje već neko vrijeme.

Twitter je možda preopterećen ili ima kratkotrajnih poteškoća u radu. Pokušajte ponovno ili potražite dodatne informacije u odjeljku Status Twittera.

    Možda bi vam se svidjelo i ovo:

    ·